Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN272201100019I
Award Date
6/1/11
Last Date to Order
5/31/18
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
6
Contract IDVs
Contract Awards
22
Transactions
6
Price Lists
Opportunity Stack
1
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Utah State University
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Federal Contract Vehicle
In Vitro Antimicrobial Assessments 2011-2018
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
In Vitro Antimicrobial Assessments 2011-2018
Master IDIQ
HHSN272201100019I
Indefinite Delivery Contract
22
Federal Contract Awards
Description
Update #1
BIOMEDICAL (BASIC)
Posted 6/1/11, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00005
OTHER FUNCTION - IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY.
Close Out
$0
2/21/20
4
OTHER FUNCTION - IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY.
Other Administrative Action
$0
12/28/17
3
OTHER FUNCTION - IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY.
Other Administrative Action
$0
10/26/15
2
OTHER FUNCTION - IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY.
Other Administrative Action
$0
11/26/13
1
OTHER - IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY.
Supplemental Agreement for work within scope
$0
5/1/12
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN272201100019I-HHSN27200003
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to Utah State University (USU) for $150,742.00. The contract is a Delivery Order under the "In Vitro Antimicrobial Assessments 2011-2018" Indefinite Delivery/Indefinite Quantity (IDIQ) Master Contract. USU, as a large public research university, will provide in vitro assessments of compounds against a comprehensive virus panel for Task B07 of the IDIQ. The contract has no set-aside designation. USU has also received a subcontract from the University of Texas Medical Branch at Galveston (UTMB) to conduct a similar in vitro assessment of compounds. UTMB, a major academic medical center, frequently partners with federal agencies on biomedical research and healthcare contracts and grants, often in the areas of infectious disease, medical countermeasures, and emergency preparedness.
Utah State University
$150.7k
9/26/11
12/31/12
12/4/14
Delivery Order HHSN272201100019I-HHSN27200001
This federal contract award is a delivery order issued under the In Vitro Antimicrobial Assessments 2011-2018 indefinite delivery vehicle (IDV) held by Utah State University (USU), a public research university in Logan, Utah. The $401,435 firm fixed price contract is for the university to conduct in vitro assessments of antimicrobial activity against viruses for the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS). The work will be performed at USU's facilities in Logan, Utah. No set-aside designation was used for this award, reflecting USU's status as a large public institution. USU has extensive experience supporting federal agencies through prime contracts, subcontracts, and grants, particularly in areas related to its land-grant mission such as agriculture, environmental sciences, and public health research.
Utah State University
$401.4k
6/2/11
12/31/12
3/14/13
Delivery Order HHSN272201100019I-75N93018F00022
1100019I UTAH STATE UNIVERSITY; IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY AGAINST RESPIRATORY VIRUSES; TO B29 RDB6 BASE TASK ORDER FUNDING; SPLIT CANS; $44,496
Utah State University
$51.9k
5/14/18
5/29/19
6/25/18
Delivery Order HHSN272201100019I-HHSN27200005
: IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY
Utah State University
$0
9/17/12
9/16/13
9/17/12
Delivery Order HHSN272201100019I-75N93018F00021
This federal contract was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Utah State University (USU), a public research university located in Logan, Utah. The contract, valued at $437,596, is a delivery order under a larger indefinite delivery contract titled "In Vitro Antimicrobial Assessments 2011-2018." The contract scope is to conduct in vitro assessments for antimicrobial activity, with a completion date of May 22, 2019. The contract is a firm fixed price type and does not have a set-aside designation. Utah State University has experience providing various animal laboratory testing services to federal agencies like the U.S. Department of Agriculture, as well as conducting research and development work for organizations such as NASA.
Utah State University
$437.6k
5/2/18
5/22/19
3/14/19
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY
Added: Sep 02, 2009 11:39 am IntroductionThe National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID's Division of Microbiology and Infectious Diseases (DMID) has a requirement for developing and providing in vitro assays in order to advance the development of therapeutics for infectious diseases.Description NIAID's role in developing medical products to counter emerging, re-emerging and other infectious diseases, as well as agents of bioterrorism, is part of a larger national strategy, involving multiple governmental agencies. As such, NIAID supports integrated efforts in basic and applied research, product development, and technology development based on national priorities for medical products. Since 2001, NIAID has established a comprehensive infrastructure with extensive resources that support all levels of biodefense research. With this solid framework of research and product development resources for biodefense in place, NIAID is now transitioning this infrastructure to provide the flexibility required to meet the challenges of emerging, re-emerging and other infectious diseases in addition to biodefense.The use of in vitro assays helps advance our understanding of infectious diseases as well as the development of therapeutics and vaccines. Therefore, DMID is committed to developing and providing in vitro assays to benefit the research community and public health.For the most part, in vitro assay services and other research resources are currently provided through multiple, specialized programs. DMID now seeks to adopt an integrated approach to the provision of services and resources by creating unified, comprehensive, coordinated programs. This strategy is being employed to: advance science by promoting cross-fertilization across and within disciplines and approaches; serve the research community more conveniently; achieve efficient use of resources through economy of scale and avoidance of duplication; and provide the flexibility needed to respond to changing priorities. Accordingly, DMID is establishing the In Vitro Assessments for Antimicrobial Activity program, which will utilize the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism.Under IDIQ contracts, base contract awards are made to multiple offerors that successfully propose a general approach to the technical requirements of the solicitation, providing a guaranteed minimum award. Task Orders for specific tasks requiring specialized expertise are competitively solicited and funded within the program Contractor pool. DMID is replacing multiple pathogen or class specific solicitations with one broad IDIQ solicitation for multiple contracts to cover all areas of current and potential future interests.The work under this acquisition has been broken into five Parts. Work under Parts A, B and D require Biosafety Levels (BSL) 1 through 3, and compliance with Select Agent Regulations through the Centers for Disease Control (CDC) and/or the United States Department of Agriculture (USDA) (42 CFR Part 73, 7 CFR Part 331, and/or 9 CFR Part 121). For offerors submitting proposals for more than one Part, separate Technical and Business Proposals are required for each Part. Offerors may not submit more than one proposal per Part A, B, C, D or E.1. Part A - Bacteria and Fungi - Will support the development and use of in vitro assays for routine screening of products against a wide range of bacterial and fungal pathogens, to include all bacteria and fungi on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm) and other bacterial and fungal pathogens that cause disease in humans.2. Part B - Viruses - Will support the development and use of in vitro assays for routine screening products against a wide range of viral pathogens, to include all viruses on the NIAID Category A, B and C Priority Pathogens list, and other viral pathogens that cause disease in humans.3. Part C - Parasites and Vectors - Will support the development and use of in vitro assays for routine screening of products against a wide range of parasitic pathogens, to include all parasites and vectors on the NIAID Category A, B and C Priority Pathogens list, and other parasitic pathogens that cause disease in humans. This Part also includes screening against cell lines from insect and other arthropod vectors.4. Part D - Toxins - Will support the development and use of in vitro assays for routine screening of products against a wide range of toxins, to include all toxins on the NIAID Category A, B, and C Priority Pathogens list.5. Part E - Central Data Management System - Will support the development, implementation, operation, and maintenance of a Central Data Management System to support all activities conducted under Parts A, B, C and D. In order to qualify for work under Part E, Contractors must also qualify for one or more of Parts A-D. Offerors submitting a proposal under Parts A, B, C and/or D DO NOT have to submit a proposal for Part E.For the purposes of this acquisition:• Assays - in vitro procedures for determining the concentration, purity, and/or biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation.• Products - broadly defined and include therapeutic substances targeting the host or the pathogen. • Pathogens - bacteria, viruses, parasites, toxins and fungi, including NIAID Category A, B and C Priority Pathogens.• Toxins - microbial toxins as they relate to human disease, and other toxins on the NIAID Category A, B and C Priority Pathogens list (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm).• Vectors - insects or other arthropods that carry pathogens from infected to uninfected hosts.• Pathogens of interest - must be pathogens which cause disease in humans; however surrogate human pathogens may be used for diseases where human pathogens cannot be studied. • Reagents - biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins and vectors.The following factors will be considered when evaluating proposals:• adequacy and appropriateness of the general technical approach for in vitro assays, to include protocol and assay development, conduct of product susceptibility studies; soundness, feasibility and completeness of the technical approach to pathogen production and characterization.• adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity. • availability of adequate, accredited facilities, with biocontainment appropriate for the pathogens proposed; availability and appropriateness of equipment and other resources necessary for the proposed in vitro assays including IT systems, data management, and capabilities for the receipt, storage, shipping and inventory of products, pathogens, specimens, and reagents; and adequacy of institutional biosafety program.It is anticipated that multiple IDIQ base contracts will be awarded for a 7-year period of performance beginning on or about September 10, 2010.Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about September 18, 2009, and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
NIAID-DMID-NIHAI2009066
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
9/2/09, 11:39 AM